AbbVie vs Astrazeneca: revenue, profit, margins and growth compared
AbbVie brought in $61.2B of revenue in fiscal 2025, Astrazeneca $58.7B in fiscal 2025. Revenue changed by +8.6% at AbbVie and +8.6% at Astrazeneca on the year before, so Astrazeneca grew faster. AbbVie kept 6.9% of its revenue as net profit, Astrazeneca 17.4%. Free cash flow was $17.8B at AbbVie and $11.8B at Astrazeneca.
Fiscal years as each company reports them; the two may end in different months.
Questions about AbbVie and Astrazeneca
Which is bigger by revenue, AbbVie or Astrazeneca?
AbbVie is bigger by revenue: $61.2B in fiscal 2025, against $58.7B for Astrazeneca in fiscal 2025.
Which keeps more of its revenue as profit, AbbVie or Astrazeneca?
AbbVie had a net margin of 6.9% in fiscal 2025; Astrazeneca had 17.4% in fiscal 2025.
Which grew revenue faster, AbbVie or Astrazeneca?
In their latest fiscal years revenue changed by +8.6% at AbbVie and +8.6% at Astrazeneca.
Where do these numbers come from?
From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.